Octane Portfolio
Company Presentations

Rapid exosome-based liquid biopsy device for early multi-cancer screening

2Pi-Sigma Corp. has developed a proprietary NG-LFA (Next Generation Lateral Flow Assay) platform, a microfluidics platform, and a new exosome assay enabling the development of rapid exosome-based liquid biopsy cancer screening tests and devices utilizing a novel proprietary antibody-antigen pair for early detection of the majority of cancers as a fully integrated device using only a few microliters of blood. Product designated as NovoScreenTM. The performance of the antibody-antigen pair (UCD1) in cancer detection has been shown in a validation trial with 837 serum samples from cancer patients and healthy subjects with 95.6% sensitivity and 92.2% specificity.

Alyve Medical is transforming musculoskeletal care with revolutionary sensor technologies.

Alyve Medical is at the forefront of transforming musculoskeletal rehabilitation and motion assessment with its cutting-edge technologies. Their pioneering therapeutic wearable, Neuralign S™, is specifically designed to address shoulder pain and enhance function. Representing the next generation of neuromuscular electrical stimulation (NMES), Neuralign S™ harnesses the power of patented Motion Activated Stimulation™, delivering unique stimulation patterns and superior outcomes. Shoulder pain ranks as the third most prevalent reason for seeking musculoskeletal care, making Neuralign S™ exceptionally relevant. With a total addressable market (TAM) exceeding $10B, the potential for growth is substantial.

Diagnostic Sensors
and Data Science for Urology

Bright Uro is developing advanced Diagnostic Sensors and Data Science for Urology. Leveraging IP from the Cleveland Clinic, Bright Uro has developed the most comfortable, accurate, and efficient way to perform Urodynamics.

Glean is the first and only way to perform wireless, catheter-free urodynamic monitoring and will help millions of Americans dealing with Overactive Bladder, Incontinence, and Prostate issues. Glean is also the first connected device for Urodynamics and will enable the integration of AI and Machine Learning to increase efficiency and improve outcomes. Bright Uro is like iRhythym for Urology but with better reimbursement.

Low Level Microbicidal Light for Treatment of Yeast & Bacterial Vaginosis…without drugs!

Microbicidal light therapy device treating both yeast & bacterial vaginosis. The prescriptive device is designed for use at home, as needed, when needed, based on familiar, recurrent symptom and whose use may be managed by the clinician. The Cern Device™ avoids use of toxic antifungal/antibiotics and is designed for those, for whom, drug-based therapies are neither effective, appropriate, or desired. Cern has received utility & design patents, along with supportive 3rd party assessment of “Freedom to Operate”. Based on FDA Pre-Submission, we are slated to be FDA Class II, 510K de novo clearance path.

IMS is creating a platform for monitoring blood chemistry for health tracking.

Traditional healthcare involves multiple doctor and lab visits and is not sustainable for managing health and preventing diseases. A new approach requires continuous monitoring of various indicators to track health status. To achieve this, a scalable, affordable, and accurate personal health monitoring tool is needed to monitor metabolic and physiological markers. IMS Inc. has developed such a system. Using a single device, this system continuously monitors biochemical health markers such as glucose and lactate and physiological markers like tissue temperature and pH. It uses advanced semiconductors and nanotechnology to deliver exceptional performance at extremely small sizes.

Democratizing touchless control for public health and safety.

NZ Technologies Inc. (NZTech) pioneers touchless interactions for healthcare and beyond. Since 2015, we’ve combined embedded hardware, software, AI, and machine learning to create TIPSO, our flagship product, enabling surgeons to control equipment and imaging without contact. Our HoverTap platform extends touchless control to various hospital systems, minimizing health risks. We collaborate with experts in minimally invasive surgery to innovate continually. NZTech’s mission is to democratize contactless interaction, reducing disease transmission. Join us in creating a safer tomorrow with groundbreaking solutions for healthcare.

Non invasive Monitoring and Care Management Decision Support Platform for Chronic Wounds, Dermatology, and Cosmetics

Rubitection’s assessment and management system provides a reliable decision support platform for chronic wounds and dermatological conditions. Rubitection’s solution solves a $26 billion healthcare problem by providing care providers with a low cost reliable tool to assess and manage the care of chronic wounds and dermatological conditions. A low risk FDA pathway as a class I FDA device allows a quick path to a $4.2 billion market. Hybrid sales and distribution partnerships enable $240 million in sales within 6 years of product launch. We are currently raising $2 million in seed funding with 40% closed. We are identifying our final set of investors to reach our goal.

Harnessing the regenerative power of fat, the largest source of stem cells

Sayenza Bio is a leading clinical stage biotechnology company committed to improving patient lives by harnessing the regenerative power of fat, the body’s largest source of stem cells, for limitless aesthetic and regenerative medicine applications. At Sayenza, our passionate, doctor-driven team unites cutting-edge scientific innovation with vast commercial expertise, propelling us towards transformative breakthroughs in healthcare.

We build novel stabilization technology to improve hand tremors

Steadiwear aspires to become the world’s foremost authority in tremor solutions. Leveraging the success of our transformative product, the Steadi-Two, they are enhancing the quality of life & independence of those battling hand tremors. Their expanded groundbreaking product lineup includes the miniaturized Steadi-Three & Steadi-Cup. By pushing technological boundaries and providing personalized care, they aim to elevate the everyday experiences of their users globally. Their team is well equipped to tackle this problem with 50+ years of experience across business and product development. Steadiwear is 20% committed on their pre-seed equity round of $1.2M.

Swiftsure provides nursing tools that improve efficiency and patient outcomes.

Swiftsure provides nurses with tools that improve efficiency and patient outcomes. Our flagship product, The SwishKit, is designed to reduce harmful colonization of oral bacteria to decrease ventilator-acquired pneumonia, the most common, costly, and fatal of all ICU hospital-acquiredventilator-acquired infections.

Vessl’s mission is to make a fulfilling life more comfortable.

Vessl Prosthetics Inc was founded by two passionate innovators, a biomedical engineer and a clinical anatomist. Driven to improve the lives of amputees, Vessl has designed the isoform socket for below-knee amputees. This automatically adjusting socket eliminates the need for constant manual adjustments, saving time and money for both amputees and prosthetists. Vessl is collaborating on product validation with 5 Veterans Affairs healthcare centers. With a mission to enhance the comfort and potential of amputees, Vessl is revolutionizing the prosthetics industry, supported by a successful pre-seed funding round, a robust clinic pipeline, and a team of exceptional advisors.